845305-86-4

Basic information

• Product Name: 5-BROMO-PYRIDINE-2-CARBOXYLIC ACID DIMETHYLAMIDE
• Synonyms: 5-BROMO-PYRIDINE-2-CARBOXYLIC ACID DIMETHYLAMIDE;5-broMo-N,N-diMethylpicolinaMide;5-BroMo-N,N-diMethylpyridine-2-carboxaMide, 96%
• CAS NO: 845305-86-4
• Molecular Formula: C₈H₉BrN₂O
• Molecular Weight: 229.07
• Mol File: 845305-86-4.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-BROMO-PYRIDINE-2-CARBOXYLIC ACID DIMETHYLAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-PYRIDINE-2-CARBOXYLIC ACID DIMETHYLAMIDE(845305-86-4)
• EPA Substance Registry System: 5-BROMO-PYRIDINE-2-CARBOXYLIC ACID DIMETHYLAMIDE(845305-86-4)

Safety Data

• Hazardous Substances Data: 845305-86-4(Hazardous Substances Data)

Usage

Uses

5-Bromo-N,N-dimethylpyridine-2-carboxamide is used as an organic chemical synthesis intermediate.

Upstream product

• 30766-11-1 5-bromoisonicotinic acid 
• 137178-88-2 5-bromopyridine-2-carbonyl chloride 
• 506-59-2 N,N-dimethylammonium chloride 
• 97483-77-7 2-Cyano-5-bromopyridine 
• 124-40-3 dimethyl amine 

Downstream Products

• 1006876-27-2 N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carboxamide 
• 1433497-55-2 methyl 4-[3-(3,5-di-tert-butylphenyl)-2-[6-(dimethylcarbamoyl)-3-pyridyl]-3,4-dihydropyrazol-5-yl]benzoate 
• 1020855-13-3 N,N-dimethyl-5-[3-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-5-[(5-methylpyrazin-2-yl)carbamoyl]phenoxy]pyridine-2-carboxamide 

Relevant articles and documents

N2-carbamylaryl-2-aminopyrimidine derivative and medical application thereof

The invention provides an N2-carbamylaryl-2-aminopyrimidine derivative and a medical application thereof. The N2-carbamylaryl-2-aminopyrimidine derivative provided by the invention comprises an optical isomer of the N2-carbamylaryl-2-aminopyrimidine derivative and pharmaceutically acceptable salt thereof. Pharmacodynamic research shows that the traditional Chinese medicine composition has no toxicor side effect, the compound has an FLT3 inhibitory activity. The proliferation inhibition activity is realized on various leukemia cell strains; a medium inhibition effect is achieved on breast cancer cells; moreover, the polypeptide is effective for multiple mutations of AML, such as internal tandem repeat mutation of a near-membrane structural domain and D835 point mutation of an activated ring in a kinase structural domain, almost has no inhibition effect on c-KIT, can overcome drug resistance brought by clinical point mutation, can reduce toxic and side effects of bone marrow inhibition,and can be applied to preparation of antitumor drugs. The structures of the general formulas Ia and Ib of the N2-carbamylaryl-2-aminopyrimidine derivative are shown in the specification,

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.